- Home
- FEBO vs BRTX Comparison
FEBO vs BRTX Comparison
Compare FEBO & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- BRTX
- Stock Information
- Founded
- FEBO 1993
- BRTX 1997
- Country
- FEBO Hong Kong
- BRTX United States
- Employees
- FEBO N/A
- BRTX N/A
- Industry
- FEBO
- BRTX Managed Health Care
- Sector
- FEBO
- BRTX Health Care
- Exchange
- FEBO Nasdaq
- BRTX Nasdaq
- Market Cap
- FEBO 12.7M
- BRTX 12.6M
- IPO Year
- FEBO 2023
- BRTX N/A
- Fundamental
- Price
- FEBO $1.09
- BRTX $1.61
- Analyst Decision
- FEBO
- BRTX Strong Buy
- Analyst Count
- FEBO 0
- BRTX 1
- Target Price
- FEBO N/A
- BRTX $18.00
- AVG Volume (30 Days)
- FEBO 5.5K
- BRTX 253.7K
- Earning Date
- FEBO 07-07-2025
- BRTX 08-12-2025
- Dividend Yield
- FEBO N/A
- BRTX N/A
- EPS Growth
- FEBO N/A
- BRTX N/A
- EPS
- FEBO N/A
- BRTX N/A
- Revenue
- FEBO $17,110,653.00
- BRTX $391,000.00
- Revenue This Year
- FEBO N/A
- BRTX $391.52
- Revenue Next Year
- FEBO N/A
- BRTX $3.50
- P/E Ratio
- FEBO N/A
- BRTX N/A
- Revenue Growth
- FEBO 11.58
- BRTX 161.54
- 52 Week Low
- FEBO $0.93
- BRTX $1.21
- 52 Week High
- FEBO $17.68
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- FEBO 45.42
- BRTX 46.78
- Support Level
- FEBO $1.06
- BRTX $1.57
- Resistance Level
- FEBO $1.15
- BRTX $1.72
- Average True Range (ATR)
- FEBO 0.06
- BRTX 0.13
- MACD
- FEBO 0.00
- BRTX -0.01
- Stochastic Oscillator
- FEBO 39.47
- BRTX 20.65
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care c principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.